Trial reportSpinal cord series and cases2019
Treatment of at-level spinal cord injury pain with botulinum toxin A.
Trial report in Spinal cord series and cases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 4 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- Is Botulinum Toxin Effective in Treating Orofacial Neuropathic Pain Disorders? A Systematic Review.Toxins · 2023Pooled it
- Efficacy and safety of different drug treatments in patients with spinal-cord injury-related neuropathic pain: a network meta-analysis.Spinal cord · 2022Pooled it
- Pooled it
- Comparative Efficacy and Safety of 11 Drugs as Therapies for Adults With Neuropathic Pain After Spinal Cord Injury: A Bayesian Network Analysis Based on 20 Randomized Controlled Trials.Frontiers in neurology · 2022Pooled it
- Treatment of at-level spinal cord injury pain with botulinum toxin A.Spinal cord series and cases · 2019Trial
- Medications for Managing Central Neuropathic Pain as a Result of Underlying Conditions-A Systematic Review.Neurology international · 2025Review
- Botulinum toxin type A treatment for persistent neuropathic pain in the soles after cervical spinal cord injury: A case report.Turkish journal of physical medicine and rehabilitation · 2024Article
- The efficacy of botulinum toxin in neuropathic pain: a systematic review.British journal of pain · 2024Article
- Botulinum toxin in the rehabilitation of painful syndromes: multiperspective literature analysis, lexical analysis and systematic review of randomized controlled trials.European journal of translational myology · 2024Article
- Combined rehabilitation therapy with botulinum toxin to the upper limbs for acute spinal cord injury: A case report.Spinal cord series and cases · 2024Article
- Effectiveness of Botulinum Toxin in the Treatment of Neuropathic Pain: A Literature Review.Cureus · 2023Review
- A Systematic Review of the Interventions for Management of Pain in Patients After Spinal Cord Injury.Cureus · 2023Review
- Diagnosis and Management of Neuropathic Pain in Spine Diseases.Journal of clinical medicine · 2023Review
- Article
- A clinical review of the use of Botulinum Toxin type A in managing central neuropathic pain in patients with spinal cord injury.The journal of spinal cord medicine · 2022Review
- Central Neuropathic Pain Syndromes: Current and Emerging Pharmacological Strategies.CNS drugs · 2022Review
- Botulinum Toxin and Neuronal Regeneration after Traumatic Injury of Central and Peripheral Nervous System.Toxins · 2020Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Study design: Randomized, double-blinded, placebo-controlled, cross-over study. Objective: To explore whether botulinum toxin A (BoNTA) could be effective for treating at-level spinal cord injury (SCI) pain. Setting: Outpatient SCI clinic, New York, USA. Methods: Participants were randomized to receive subcutaneous injections of either placebo or BoNTA with follow-up (office visit, telephone, or e-mail) at 2, 4, 8, and 12 weeks to assess the magnitude of pain relief post injection. Crossover of participants was then performed. Those who received placebo received BoNTA, and vice versa, with follow-up at 2, 4, 8, and 12 weeks. Results: Eight participants completed at least one of the two crossover study arms. Four completed both arms. The median age of the eight participants was 45 years (range 32-61 years) and 75% were male. All had traumatic, T1-L3 level, complete SCI. Although our data did not meet statistical significance, we noted a higher proportion of participants reporting a marked change in average pain intensity from baseline to 8 and 12 weeks post-BoNTA vs. post-placebo (33% vs. 0%). At 2 and 4 weeks post-BoNTA, almost all participants reported some degree of reduced pain, while the same was not seen post-placebo (83% vs. 0%). Conclusion: The subcutaneous injection of BoNTA may be a feasible approach for the control of at-level SCI pain and is worthy of further study. Sponsorship: The onabotulinumtoxinA (BOTOX) used in this study was provided by Allergan (Irvine, CA).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.